According to a recent assessment by the European Medicines Agency (EMA), there is no evidence linking the weight-loss drugs Ozempic and Wegovy to an increased risk of suicide. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed available data on these drugs and concluded that there is no established causal link between their use and suicide risk. The review was prompted by concerns raised by a small number of reports of suicidal behavior in patients taking these medications. While the EMA recognizes the importance of monitoring the safety of drugs, it has determined that there is no need for any changes to the current product information for Ozempic and Wegovy.
Source: Gizmodo.Com
